Saturday, August 30, 2025
  • About Web3Wire
  • Web3Wire NFTs
  • .w3w TLD
  • $W3W Token
  • Web3Wire DAO
  • Media Network
  • RSS Feed
  • Contact Us
Web3Wire
No Result
View All Result
  • Home
  • Web3
    • Latest
    • AI
    • Business
    • Blockchain
    • Cryptocurrencies
    • Decentralized Finance
    • Metaverse
    • Non-Fungible Token
    • Press Release
  • Technology
    • Consumer Tech
    • Digital Fashion
    • Editor’s Choice
    • Guides
    • Stories
  • Coins
    • Top 10 Coins
    • Top 50 Coins
    • Top 100 Coins
    • All Coins
  • Exchanges
    • Top 10 Crypto Exchanges
    • Top 50 Crypto Exchanges
    • Top 100 Crypto Exchanges
    • All Crypto Exchanges
  • Stocks
    • Blockchain Stocks
    • NFT Stocks
    • Metaverse Stocks
    • Artificial Intelligence Stocks
  • Events
  • News
    • Latest Crypto News
    • Latest DeFi News
    • Latest Web3 News
  • Home
  • Web3
    • Latest
    • AI
    • Business
    • Blockchain
    • Cryptocurrencies
    • Decentralized Finance
    • Metaverse
    • Non-Fungible Token
    • Press Release
  • Technology
    • Consumer Tech
    • Digital Fashion
    • Editor’s Choice
    • Guides
    • Stories
  • Coins
    • Top 10 Coins
    • Top 50 Coins
    • Top 100 Coins
    • All Coins
  • Exchanges
    • Top 10 Crypto Exchanges
    • Top 50 Crypto Exchanges
    • Top 100 Crypto Exchanges
    • All Crypto Exchanges
  • Stocks
    • Blockchain Stocks
    • NFT Stocks
    • Metaverse Stocks
    • Artificial Intelligence Stocks
  • Events
  • News
    • Latest Crypto News
    • Latest DeFi News
    • Latest Web3 News
No Result
View All Result
Web3Wire
No Result
View All Result
Home Press Release GlobeNewswire

Liquidia and Pharmosa Biopharm Expand Collaboration to Develop Sustained Release Inhaled Treprostinil (L606)

October 2, 2024
in GlobeNewswire
Reading Time: 10 mins read
5
SHARES
244
VIEWS
Share on TwitterShare on LinkedInShare on Facebook
  • Liquidia amends exclusive license to include key markets in Europe, Japan and elsewhere
  • Liquidia also obtains rights to Pharmosa’s next-generation nebulizers for use with L606
  • Pharmosa to receive $3.5 million upfront and up to $157.75 million in additional development and sales milestones tied to commercial sales outside of North America

MORRISVILLE, N.C., Oct. 02, 2024 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, and Pharmosa Biopharm (Pharmosa) today announced that they have amended the current exclusive licensing agreement for the development and commercialization of L606, an inhaled, sustained-release formulation of treprostinil currently being evaluated in a clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The amended agreement expands Liquidia’s licensed territory beyond North America to include key markets in Europe, Japan and elsewhere. Pharmosa will retain certain territories, including China, Korea, Taiwan, Middle East, North Africa, Turkey and Southeast Asia.

Liquidia has also obtained certain rights to Pharmosa’s next-generation smart-technology nebulizers for use with its proprietary liposomal drug formulations. Unlike current nebulized treatments for PAH and PH-ILD, these palm-sized, lightweight, virtually silent nebulizers provide portability like a dry-powder inhaler and rapidly deliver a dose using breath-actuated smart technology that adapts to a patient’s normal breathing pattern.

Dr. Rajeev Saggar, Chief Medical Officer of Liquidia, stated: “This is a great example of our approach to research and development in pulmonary hypertension. This partnership has the potential to be transformational for people living with PAH and PH-ILD, as it will combine Liquidia’s expertise as a leader in the field of pulmonary hypertension with Pharmosa’s deep experience in inhaled liposomal formulations. We are delighted by the interest from the global medical and patient communities, many of which lack access to inhaled formulations of treprostinil, as we prepare to initiate the L606 pivotal study in PH-ILD later this year. We are also encouraged by the recent scientific advice from the European Medicines Agency that supports our plan to proceed with the study as designed.”

Pei Kan, Ph.D., President of Pharmosa, added: “This expanded partnership with Liquidia is a strong endorsement for our L606 programs and our contribution to the fight against pulmonary hypertension including PAH and PH-ILD. With more than 100,000 PAH and PH-ILD patients in the major countries outside North America, improvements of the treatment strategies in this region are essential since there is no approved treatment for PH-ILD outside the U.S. We believe Liquidia’s commitment to move quickly and execute its global clinical program will accelerate the potential for long-term value creation for both parties in this partnership.”

Consistent with the agreement from June 2023, Liquidia will be responsible for the development, regulatory and commercial activities of L606 in the expanded territory. Pharmosa will continue to manufacture clinical and commercial supplies of L606. In consideration for these incremental exclusive rights, Liquidia will pay Pharmosa an upfront payment of $3.5 million and up to $157.75 million in additional milestone payments for the development of PAH and PH-ILD indications and commercial sales outside of North America. Royalties payable by Liquidia to Pharmosa on global net sales of L606 have not changed and remain two tiers of low, double-digit royalties as set forth in the original agreement.

Clinically, L606 continues to generate encouraging data in an open-label safety study in the United States in both PAH and PH-ILD. As reported in a poster presentation at the 2024 American Thoracic Society International Conference, the tolerability and titratability profile of L606 observed to date has been favorable up to the maximum dose allowed in the study of 378 mcg twice daily, a dosage comparable to 26 to 28 breaths of Tyvaso administered four times daily. Pharmacokinetic studies in healthy volunteers demonstrated therapeutic levels of L606 up to 12 hours and 7-times lower peak plasma concentration compared to Tyvaso®. The increased apparent half-life of L606, in concert with comparable systemic exposure and clearance rate, suggests that L606 provides controlled, continuous drug coverage during sleeping and waking hours, and supports twice-daily administration using a breath-actuated, smart-technology nebulizer.

About L606 (liposomal treprostinil) Inhalation Suspension

L606 is an investigational, liposomal formulation of treprostinil administered twice-daily with a short-duration next-generation nebulizer. The L606 suspension uses Pharmosa’s proprietary liposomal formulation to encapsulate treprostinil which can be released slowly at a controlled rate into the lung, enhancing drug exposure over an extended period and reducing local irritation of the upper respiratory tract. L606 is currently being evaluated in an open-label study in the United States for treatment of pulmonary arterial hypertension (PAH) with a planned pivotal study for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD).

About Pulmonary Arterial Hypertension (PAH)

Pulmonary arterial hypertension (PAH) is a rare, chronic, progressive disease caused by hardening and narrowing of the pulmonary arteries that can lead to right heart failure and eventually death. Currently, an estimated 45,000 patients are diagnosed and treated in the United States. There is currently no cure for PAH, so the goals of existing treatments are to alleviate symptoms, maintain or improve functional class, delay disease progression, and improve quality of life.

About Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

Pulmonary hypertension (PH) associated with interstitial lung disease (ILD) includes a diverse collection of up to 150 different pulmonary diseases, including interstitial pulmonary fibrosis, chronic hypersensitivity pneumonitis, connective tissue disease related ILD, and sarcoidosis among others. Any level of PH in ILD patients is associated with poor 3-year survival between 30 to 35%. A current estimate of PH-ILD prevalence in the United States is greater than 60,000 patients, though population growth in many of these underlying ILD diseases is not yet known due to factors including underdiagnosis and lack of approved treatments until March 2021 with inhaled treprostinil.

About Liquidia Corporation

Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of Liquidia’s lead candidate, YUTREPIA™ (treprostinil) inhalation powder, an investigational drug for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).  The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit https://www.liquidia.com.

About Pharmosa Biopharm

Pharmosa Biopharm Inc. (PBI) is a Taiwan-based biotechnology company focused on developing new drugs by exploiting its proprietary liposomal formulations and manufacturing technology. With regional and global strategic partnerships, PBI develops products through 505(b)(2) or hybrid applications to regulatory authorities with the intent to expand the clinical potential of existing drugs by exploiting innovative delivery formulations and medical devices. For more information, please visit https://www.pharmosa.com.tw.

Tyvaso® is a registered trademark of United Therapeutics Corporation

Cautionary Statements Regarding Forward-Looking Statements 
This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts, including statements regarding our future results of operations and financial position, our strategic and financial initiatives, our business strategy and plans and our objectives for future operations, are forward-looking statements. Such forward-looking statements, including statements regarding clinical trials, clinical studies and other clinical work (including the funding therefor, anticipated patient enrollment, safety data, study data, trial outcomes, timing or associated costs), regulatory applications and related submission contents and timelines, and our ability to execute on our strategic or financial initiatives, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein.  The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to a number of risks discussed in our filings with the SEC, as well as a number of uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment and our industry has inherent risks. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Nothing in this press release should be regarded as a representation by any person that these goals will be achieved, and we undertake no duty to update our goals or to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise. 

Contact Information

Investors:
Jason Adair
919.328.4350
jason.adair@liquidia.com

Media:
Patrick Wallace
919.328.4383
patrick.wallace@liquidia.com

About Web3Wire
Web3Wire – Information, news, press releases, events and research articles about Web3, Metaverse, Blockchain, Artificial Intelligence, Cryptocurrencies, Decentralized Finance, NFTs and Gaming.
Visit Web3Wire for Web3 News and Events, Block3Wire for the latest Blockchain news and Meta3Wire to stay updated with Metaverse News.
ShareTweet1ShareSendShare2
Previous Post

Enreach launches DialoX marketplace, expanding access to customisable AI solutions

Next Post

Radware Schedules Conference Call for Its Third Quarter 2024 Earnings

Related Posts

Voxtur Announces Financial Results Delay for Q2 2025

TORONTO and TAMPA, Fla., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Voxtur Analytics Corp. (TSXV: VXTR; OTCQB: VXTRF) ("Voxtur" or the "Company"), a North American technology company creating a more transparent and accessible real estate lending ecosystem, today announced that it will not be filing its financial results for the second...

Read moreDetails

WOLF (WOLF), Powering Byrrgis to Bring Trust and Simplicity to Crypto, Listed on BitMart Exchange

New York, NY, Aug. 29, 2025 (GLOBE NEWSWIRE) -- BitMart, a premier global digital asset trading platform, is thrilled to announce the primary listing of WOLF (WOLF) on August 27, 2025. The WOLF/USDT trading pair is now officially available for trading at 1:00 PM (UTC).Built for the next generation of crypto...

Read moreDetails

Quick Custom Intelligence Extends their Title Sponsorship of the Raving Conferences into 2026

SAN DIEGO, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Quick Custom Intelligence (QCI), the industry leader in AI-powered analytics and operational intelligence, announced today that it will extend its role as the Title Sponsor of three Raving Conferences for 2026. This decision comes after the resounding success of the 2025 events,...

Read moreDetails

Nerdisa Launches Comprehensive Software Review Platform to Help Businesses Navigate Complex Technology Decisions

New York, NY, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Nerdisa, a new software review platform, officially launches to help businesses cut through marketing noise and make informed technology decisions. The platform focuses on practical implementation insights and real-world business impact rather than technical specifications alone. The platform addresses a critical...

Read moreDetails

Acceleware Ltd. Announces Additional Extension of Private Placement Financing

CALGARY, Alberta, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Acceleware® Ltd. (“Acceleware” or the “Company”) (TSX-V: AXE), a leading innovator of cutting-edge radio frequency (“RF”) power-to-heat technologies targeting process heat for critical minerals, amine regeneration (for carbon capture and other applications), and enhanced oil production, is pleased to announce that the...

Read moreDetails

Sword Group: Availability of the H1 2025 Financial Report

According to the current regulations, Sword Group announces that its 2025 Interim Financial Report has been made available to the public. It was sent to the Commission de Surveillance du Secteur Financier (CSSF) and was also filed with the Luxembourg Stock Exchange. It can be viewed and downloaded on the...

Read moreDetails

Sword Group: H1 2025 Report of the Liquidity Agreement contracted with ODDO BHF

from 01/01/2025 au 30/06/2025 Under the liquidity contract awarded by Sword Group to ODDO BHF, as of 30/06/2025, the following resources appeared on the account of liquidity:4,088 shares€567,563- Number of transactions executed during the semester at purchase: 1 ,406 - Number of transactions executed during the semester on sale: 1,527...

Read moreDetails

Interim Report January – June 2025

Interim Report January – June 2025 Second Quarter 2025 (compared to second quarter 2024) Net sales for the quarter amounted to MSEK 4 (6) Gross margin for the quarter increased to 53% (38%) Operating loss amounted to MSEK -21 (-16) Earnings per share before and after dilution increased to SEK...

Read moreDetails

reAlpha to Present at the 27th Annual H.C. Wainwright Global Investment Conference in New York

DUBLIN, Ohio, Aug. 29, 2025 (GLOBE NEWSWIRE) -- reAlpha Tech Corp. (Nasdaq: AIRE) (“reAlpha” or the “Company”), an AI-powered real estate technology company, today announced that Chief Executive Officer Mike Logozzo and Chief Financial Officer Piyush Phadke will present at the H.C. Wainwright 27th Annual Global Investment Conference, taking place...

Read moreDetails

DIH Holding US, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

NORWELL, Mass., Aug. 29, 2025 (GLOBE NEWSWIRE) -- DIH Holding US, Inc. (“DIH” or the “Company”) (NASDAQ:DHAI) received a notice on August 26, 2025, from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”), which stated that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1)...

Read moreDetails
Web3Wire NFTs - The Web3 Collective

Web3Wire, $W3W Token and .w3w tld Whitepaper

Web3Wire, $W3W Token and .w3w tld Whitepaper

Claim your space in Web3 with .w3w Domain!

Web3Wire

Trending on Web3Wire

  • Top 5 Wallets for Seamless Multi-Chain Trading in 2025

    50 shares
    Share 20 Tweet 13
  • Unifying Blockchain Ecosystems: 2024 Guide to Cross-Chain Interoperability

    97 shares
    Share 39 Tweet 24
  • Top Cross-Chain DeFi Solutions to Watch by 2025

    54 shares
    Share 22 Tweet 14
  • Discover 2025’s Top 5 Promising Low-Cap Crypto Gems

    71 shares
    Share 28 Tweet 18
  • Alibaba Launches Qoder: An Agentic Coding Platform for Real Software

    5 shares
    Share 2 Tweet 1
Join our Web3Wire Community!

Our newsletters are only twice a month, reaching around 10000+ Blockchain Companies, 800 Web3 VCs, 600 Blockchain Journalists and Media Houses.


* We wont pass your details on to anyone else and we hate spam as much as you do. By clicking the signup button you agree to our Terms of Use and Privacy Policy.

Web3Wire Podcasts

Upcoming Events

Web 3.0 and AI Summit 2025

2025-09-11
Frankfurt
Summit

Latest on Web3Wire

  • Voxtur Announces Financial Results Delay for Q2 2025
  • WOLF (WOLF), Powering Byrrgis to Bring Trust and Simplicity to Crypto, Listed on BitMart Exchange
  • Quick Custom Intelligence Extends their Title Sponsorship of the Raving Conferences into 2026
  • Nerdisa Launches Comprehensive Software Review Platform to Help Businesses Navigate Complex Technology Decisions
  • Acceleware Ltd. Announces Additional Extension of Private Placement Financing

RSS Latest on Block3Wire

  • Covo Finance: Revolutionary Crypto Leverage Trading Platform
  • WorldStrides and HEX Announce Partnership to Offer High School and University Students Innovative Courses Designed to Improve Their Outlook in the Digital Age
  • Cathedra Bitcoin Announces Leasing of 2.5-MW Bitcoin Mining Facility
  • Global Web3 Payments Leader, Banxa, Announces Integration With Metis to Usher In Next Wave of Cryptocurrency Users
  • Dexalot Launches First Hybrid DeFi Subnet on Avalanche

RSS Latest on Meta3Wire

  • Thumbtack Honored as a 2023 Transform Awards Winner
  • Accenture Invests in Looking Glass to Accelerate Shift from 2D to 3D
  • MetatronAI.com Unveils Revolutionary AI-Chat Features and Interface Upgrades
  • Purely.website – Disruptive new platform combats rising web hosting costs
  • WEMADE and Metagravity Sign Strategic Alliance MOU to Collaborate on Blockchain Games for the Metaverse
Web3Wire

Web3Wire is your go-to source for the latest insights and updates in Web3, Metaverse, Blockchain, AI, Cryptocurrencies, DeFi, NFTs, and Gaming. We provide comprehensive coverage through news, press releases, event updates, and research articles, keeping you informed about the rapidly evolving digital world.

  • About Web3Wire
  • Web3Wire NFTs – The Web3 Collective
  • .w3w TLD
  • $W3W Token
  • Web3Wire DAO
  • Event Partners
  • Community Partners
  • Our Media Network
  • Media Kit
  • RSS Feeds
  • Contact Us

Whitepaper | Tokenomics

Crypto Coins

  • Top 10 Coins
  • Top 50 Coins
  • Top 100 Coins
  • All Coins – Marketcap
  • Crypto Coins Heatmap

Crypto Exchanges

  • Top 10 Exchanges
  • Top 50 Exchanges
  • Top 100 Exchanges
  • All Crypto Exchanges

Crypto Stocks

  • Blockchain Stocks
  • NFT Stocks
  • Metaverse Stocks
  • Artificial Intelligence Stocks

Media Portfolio: Block3Wire | Meta3Wire

Web3 Resources

  • Top Web3 and Crypto Youtube Channels
  • Latest Crypto News
  • Latest DeFi News
  • Latest Web3 News

Blockchain Resources

  • Blockchain and Web3 Resources
  • Decentralized Finance (DeFi) – Research Reports
  • All Crypto Whitepapers

Metaverse Resources

  • AR VR and Metaverse Resources
  • Metaverse Courses
Claim your space in Web3 with .w3w!
Top 50 Web3 Blogs and Websites
Web3Wire Podcast on Spotify Web3Wire Podcast on Amazon Music 
Web3Wire - Web3 and Blockchain - News, Events and Press Releases | Product Hunt
Web3Wire on Google News
  • Privacy Policy
  • Terms of Use
  • Disclaimer
  • Sitemap
  • For Search Engines
  • Crypto Sitemap
  • Exchanges Sitemap

© 2024 Web3Wire. We strongly recommend our readers to DYOR, before investing in any cryptocurrencies, blockchain projects, or ICOs, particularly those that guarantee profits.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

No Result
View All Result
  • Coins
    • Top 10 Cryptocurrencies
    • Top 50 Cryptocurrencies
    • Top 100 Cryptocurrencies
    • All Coins
  • Exchanges
    • Top 10 Cryptocurrency Exchanges
    • Top 50 Cryptocurrency Exchanges
    • Top 100 Cryptocurrency Exchanges
    • All Crypto Exchanges
  • Stocks
    • Blockchain Stocks
    • NFT Stocks
    • Metaverse Stocks
    • Artificial Intelligence Stocks

© 2024 Web3Wire. We strongly recommend our readers to DYOR, before investing in any cryptocurrencies, blockchain projects, or ICOs, particularly those that guarantee profits.

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.